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Patients planning to travel to other countries often ask 
physicians for information about appropriate vaccines 
and prevention of diarrhea and malaria. More detailed 
advice for travelers is available from the Centers for 
Disease Control and Prevention (CDC) at 
www.cdc.gov/travel. Guidelines are also available from 
the Infectious Diseases Society of America (IDSA).1
VACCINES
Common travel vaccines are listed in Table 1 on page 
84. In addition to travel-specific vaccines, all travelers 
(including children) should be up to date on routine 
vaccines. Guidelines for routine adult immunization 
have been published in a separate issue.2 
Immunocompromised or pregnant patients generally 
should not receive live virus vaccines, such as those 
for measles and yellow fever, although in some situa­
tions the benefit might outweigh the risk.
CHOLERA —  The risk of cholera in tourists is very 
low. The parenteral vaccine previously licensed in the 
US is no longer available. An oral, whole-cell recom­
binant vaccine called Dukoral is available in some 
European countries (Crucell/SBL Vaccines) and in 
Canada (Sanofi Pasteur). It is not currently recom­
mended for routine use in travelers, but might be con­
sidered for those who plan to work in refugee camps 
or as healthcare providers in endemic areas.
HEPATITIS A —  Hepatitis A vaccine, which is now 
part of routine childhood immunization in the US, is 
recommended for all unvaccinated travelers going 
anywhere other than Australia, Canada, western 
Europe, Japan or New Zealand.3
Vaccination of adults and children usually consists of 
two IM doses separated by 6-18 months. Additional 
booster doses are not needed.4,5 Two hepatitis A vac­
cines are available in the US: Havrix and Vaqta.
Patients who received a first dose of one vaccine will 
respond to a second dose of the other. Second doses 
given up to 8 years after the first dose have produced 
protective antibody levels.6
Antibodies reach protective levels 2-4 weeks after the 
first dose. Even when exposure to the disease occurs 
sooner than 4 weeks after vaccination, the traveler is 
usually protected because of the relatively long incu­
bation period of hepatitis A (average 28 days). For 
immunosuppressed patients and those with chronic 
liver disease who will be traveling to an endemic area 
in <2 weeks, immune globulin (0.02 mL/kg IM) 
should be given in addition to the initial dose of vac­
cine. The same dose should be given to children 
under 1 year of age and other travelers who cannot 
receive the vaccine if traveling for <3 months; a dose 
of 0.06 mL/kg IM should be given if  traveling for >3 
months. For travel durations of >5 months, the dose 
should be repeated.7
HEPATITIS B —  Vaccination against hepatitis B is 
recommended for travelers going to intermediate- or 
high-risk areas (see Table 2 for low-risk areas). 
Travelers going anywhere who engage in behaviors 
that may increase the risk of transmission, such as 
unprotected sexual contact with new partners, dental 
treatment, skin perforation practices (tattoos, acupunc­
ture, ear piercing) or invasive medical treatment 
(injections, stitching), should be immunized against 
hepatitis B.
Two hepatitis B vaccines are available in the US: 
Engerix-B and Recombivax-HB. Primary immuniza­
tion usually consists of 3 doses given IM at 0, 1 and 6 
months. An alternate schedule of 3 doses given at 0, 1 
and 2 months, followed by a fourth dose at 12 months, 
is approved for Engerix-B in the US. A 2-dose sched­
ule of adult Recombivax-HB at 0 and 4-6 months is 
approved in the US for adolescents 11-15 years old. An
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1440 EU IM (1 mL) 
50 U IM (1 mL)
1-18 yrs 
1-18 yrs
720 EU IM (0.5 mL) 
25 U IM (0.5 mL)
0 and 6-12 mos 
0 and 6-18 mos
Probably lifelong 






20 mcg IM (1 mL) 
10 mcg IM (1 mL)
Birth-19 yrs 
Birth-19 yrs
10 mcg IM (0.5 mL) 
5 mcg IM (0.5 mL)
0, 1 and 6 mos 
0, 1 and 6 mos
Probably lifelong 
after completion of 
primary series
Hepatitis A/B




— 0, 1 and 6 mos Probably lifelong 






0.5 mL IM 
1 mL SC
Not approved 
for <17 yrs 
1-3 yrs 
>3 yrs
0.5 mL SC 
1 mL SC
0, 28 days
0, 7 and 14 or 
(preferably) 30 days
No data
Not established; a 
single booster is 
usually given after 





50 mcg of each 
antigen SC (0.5 mL)
>2 yrs2 50 mcg of each 
antigen SC (0.5 mL)
Single dose Repeat every 5 




4 mcg of each 
antigen IM (0.5 mL) 
(18-55 yrs)
>2 yrs 4 mcg of each 
antigen IM (0.5 mL)
Single dose Repeat every 5 






>2.5 IU of rabies 
antigen IM (1 mL)
>2.5 IU of rabies 
antigen IM (1 mL)
Birth
Birth
>2.5 IU of rabies 
antigen IM (1 mL)
>2.5 IU of rabies 
antigen IM (1 mL)
0, 7 and 21 
or 28 days4
0, 7 and 21 
or 28 days4
Routine boosters 
not necessary; for 





serologic testing is 
recommended 
every 2 yrs with 







1 cap PO (contains 
2-6x109 viable 
CFU of S. typhi 
Ty21a)




1 cap PO (contains 
2-6x109 viable 
CFU of S. typhi 
Ty21a)
25 mcg IM (0.5 mL)
1 cap every other 
day x 4 doses
Single dose
Repeat every 5 yrs 
if ongoing risk





4.74 log10 plaque 
forming units of 
17D204 attenuated 
YF virus SC (0.5 mL)
>9 mos 4.74 log10 plaque Single dose 
forming units of 
17D204 attenuated 
YF virus SC (0.5 mL)
Booster dose 
every 10 yrs 
if ongoing risk
1. Protection likely lasts at least 12 months after a single dose.
2. According to the CDC it is safe for children < 2 years old who require vaccination for the Hajj.
3. Repeat after three years for children vaccinated at 2-6 years of age.
4. Regimen for pre-exposure prophylaxis. If a previously vaccinated traveler is exposed to a potentially rabid animal, post-exposure prophylaxis with 
2 additional vaccine doses separated by 3 days should be initiated as soon as possible.
5. Minimal acceptable antibody level is complete virus neutralization at a 1:5 serum dilution by the rapid fluorescent focus inhibition test.
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accelerated schedule of 0, 7 and 14 days, followed by a 
booster dose at 6 months, can also be used with either 
vaccine, but is not FDA-approved.
An interrupted hepatitis B vaccination series can be 
completed without being restarted. A 3-dose series 
started with one vaccine may be completed with the 
other. Post-vaccination serologic testing is recommend­
ed for healthcare workers, infants born to HBsAg-pos- 
itive mothers, hemodialysis patients, HIV-infected and 
other immunocompromised patients, and sex- and nee­
dle-sharing partners of HBsAg-positive patients.
HEPATITIS A/B —  A combination vaccine (Twinrix) 
containing the same antigenic components as pediatric 
Havrix and Engerix-B is available for patients >18 
years old. It is given in 3 doses at 0, 1 and 6 months. 
An accelerated schedule of 0, 7 and 21-30 days with a 
booster dose at 12 months is also approved.8
The combination vaccine can be used to complete an 
immunization series started with monovalent hepatitis 
A and B vaccines. Twinrix Junior is available outside 
the US for children 1-15 years old.
Table 2. Low-Risk Areas For Hepatitis A & B* 
















* All other areas are in term ediate to high risk; vaccine is indicated.
1. Risk is in term ediate in A laska natives and is high in indigenous popula­
tions of northern Canada.
2. Risk is in term ediate in Greece, Portugal and Spain.
INFLUENZA —  Influenza may be a risk in the trop­
ics year-round and in temperate areas of the Southern 
Hemisphere from April to September. Outbreaks have 
occurred on cruise ships and on organized group tours 
in any latitude or season.9
Seasonal influenza vaccine directed against strains in 
the Northern Hemisphere is sometimes available in 
the US until the end of June and the US Advisory 
Committee on Immunization Practices (ACIP) recom­
mends that persons for whom seasonal influenza vac­
cine is indicated10 consider being vaccinated before 
travel to the Southern Hemisphere during influenza
season or to the tropics at any season, or when travel­
ing in a group with persons from the Southern 
Hemisphere during their influenza season (April- 
September).11 In some years, the vaccine strains are the 
same in both hemispheres. If the vaccine strains are 
different, high-risk patients from the Northern 
Hemisphere who travel to the Southern Hemisphere 
during that region’s influenza season could also con­
sider being immunized on arrival because the vaccine 
active against strains in the Southern Hemisphere is 
rarely available in the Northern Hemisphere.
A monovalent vaccine is available to protect against 
the currently (2009) circulating pandemic influenza A 
(H1N1) virus.12 It can be given at the same time as the 
seasonal vaccine, except not the 2 live attenuated for­
mulations together. Both the seasonal and monovalent 
influenza vaccines are prepared in eggs. 
Hypersensitivity reactions could occur.
There is no commercial influenza vaccine available for 
pathogenic strains of avian influenza (H5N1, H7N2, 
H9N2, H7N3, H7N7), but an inactivated vaccine 
against avian H5N1 is FDA-approved and is being 
included in the US Strategic National Stockpile.
JAPANESE ENCEPHALITIS —  Japanese 
encephalitis is an uncommon but potentially fatal mos­
quito-borne viral disease that occurs in rural Asia, 
especially near pig farms and rice paddies. It is usual­
ly seasonal (May-October), but may occur year-round 
in equatorial regions. The attack rate in travelers has 
been very low.13
Vaccination is recommended for travelers >1 year old 
who expect a long stay (>1 month) in endemic areas or 
heavy exposure to mosquitoes (such as adventure trav­
elers) during the transmission season. Vaccination also 
should be considered for travelers spending less than a 
month in endemic areas during the transmission season 
if they will be sleeping without air conditioning, screens 
or bed nets, or spending considerable time outside in 
rural or agricultural areas, especially in the evening or at 
night.14 Some Medical Letter consultants suggest that, 
given the rarity of the disease in US residents, compul­
sive use of insect repellents and judicious avoidance of 
exposure to mosquitoes might be reasonable alternatives 
to vaccination for short-term travelers.
Two formulations are FDA-approved in the United 
States: JE-Vax, which is a mouse-brain preparation, and 
the recently approved Ixiaro, a non-mouse-brain vac­
cine, which is preferred for use in adults, but has not 
been approved for use in children in the US.15 In clini­
cal trials, 2 doses of Ixiaro (one is not enough) appeared 






Western Europe (all countries)
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MEASLES —  The measles vaccine is no longer avail­
able in a monovalent formulation. It is available as an 
attenuated live-virus vaccine in combination with 
mumps and rubella (MMR). Adults born in or after 
1957 (1970 in Canada) and healthcare workers of any 
age who have not received 2 doses of live measles vac­
cine (not the killed vaccine that was commonly used in 
the 1960s) after their first birthday and do not have a 
physician-documented history of infection or laborato­
ry evidence of immunity should receive two doses of 
MMR vaccine, separated by at least 28 days.17
Previously unvaccinated children >12 months old 
should receive 2 doses o f MMR vaccine at least 28 
days apart before traveling outside the US. Children 
6-11 months old should receive 1 dose before travel­
ing, but will still need two subsequent doses for rou­
tine immunization, one at 12-15 months and one at 4­
6 years.
MENINGOCOCCAL —  A single dose of meningo­
coccal vaccine is recommended for adults and children 
>2 years old who are traveling to areas where epi­
demics are occurring, or to anywhere in the “meningi­
tis belt” (semi-arid areas of sub-Saharan Africa extend­
ing from Senegal and Guinea eastward to Ethiopia) 
from December to June. Saudi Arabia requires a cer­
tificate of immunization for pilgrims during the Hajj. 
Immunization should also be considered for travelers 
to other areas where Neisseria meningitidis is hyper­
endemic or epidemic, particularly for those who will 
have prolonged contact with the local population, such 
as those living in a dormitory or refugee camp, or 
working in a healthcare setting.18-20
Two quadrivalent vaccines are available against N. 
meningitidis serogroups A, C, Y and W135. Menomune 
contains meningococcal capsular polysaccharides. 
Menactra, which contains capsular polysaccharides 
conjugated to diphtheria toxoid, is preferred, but 
Menomune is an acceptable alternative. Neither vac­
cine provides protection against serogroup B, which 
does not have an immunogenic polysaccharide capsule. 
Group B infections are rare in sub-Saharan Africa.
The most common adverse reactions to Menactra have 
been headache, fatigue and malaise in addition to pain, 
redness and induration at the site of injection. The rates 
of these reactions are higher than with Menomune, but 
similar to those with tetanus toxoid. Guillain-Barre 
syndrome has been reported rarely in adolescents who 
received Menactra, but cause and effect have not been 
established.21
POLIO —  Adults who have not previously been 
immunized against polio should receive a primary
series of inactivated polio vaccine (IPV) if  traveling to 
areas where polio is still endemic (Nigeria, India, 
Pakistan, Afghanistan) or to areas with documented 
outbreaks or circulating vaccine-derived strains (see 
Table 3).22 Previously unimmunized children should 
also receive a primary series of IPV
If protection is needed within 4 weeks, a single dose 
of IPV is recommended, but provides only partial pro­
tection. Adult travelers to risk areas who have previ­
ously completed a primary series and have never had 
a booster should receive a single booster dose of IPV.
Table 3. Countries with a Risk of Polio1
Afghanistan Djibouti Niger




Burkina Faso Gambia Sierra Leone
Burundi Ghana Somalia
Cameroon Guinea Sudan






Republic of the Namibia
Congo Nepal
1. Centers for Disease Control and Prevention. Update on the Global Status 
of Polio. October 1, 2009. Available at: http://wwwnc.cdc.gov/travel/con- 
tent/in-the news/polio-outbreaks.aspx.
RABIES —  Rabies is highly endemic in parts of 
Africa, Asia (particularly India) and Central and South 
America, but the risk to travelers is generally low. Pre­
exposure immunization against rabies is recommended 
for travelers with an occupational risk of exposure, for 
those (especially children) visiting endemic areas 
where immediate access to medical treatment, particu­
larly rabies immune globulin, tends to be limited, and 
for outdoor-adventure travelers.23,24 The 2 vaccines 
available in the US (Imovax, RabAvert) are similar; 
both are given in the deltoid (not gluteal) muscle at 0,
7 and 21 or 28 days.
After a bite or scratch from a potentially rabid animal, 
patients who received pre-exposure prophylaxis 
should promptly receive 2 additional doses of vaccine 
at days 0 and 3. Without pre-exposure immunization, 
the ACIP recommends rabies immune globulin (RIG) 
and is now recommending 4 doses (over 14 days) of 
vaccine instead of 5 doses (over 28 days). Patients with 
immunosuppression should still receive 5 doses of 
vaccine.25 The reduced vaccine dosing schedule may 
not be included in the prescribing information from the 
manufacturers of the approved vaccines. According to 
the CDC, cell culture rabies vaccines available outside
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the US are acceptable alternatives to FDA-approved 
vaccines; neural tissue vaccines have high rates of seri­
ous adverse effects.26 RIG is a blood product, and its 
purity and potency may be less reliable, if it is avail­
able at all, in developing countries.
TETANUS, DIPHTHERIA AND PERTUSSIS —
Previously unimmunized children should receive 3 or 
(preferably) 4 doses of pediatric diphtheria, tetanus 
and acellular pertussis vaccine (DTaP) before travel. 
An accelerated schedule can be used beginning at age 
6 weeks, with the second and third doses given 4 
weeks after the previous dose, and the fourth dose 6 
months after the third.
Adults with an uncertain history of primary vaccina­
tion should receive 3 doses of a tetanus and diphtheria 
toxoid vaccine. Two vaccines (Adacel; Boostrix) con­
taining protein components of acellular pertussis com­
bined with diphtheria and tetanus toxoids (Tdap) are 
available for adults <64 years of age.27 One of the 3 
doses (preferably the first) should be Tdap. The first 2 
doses should be administered at least 4 weeks apart 
and the third 6-12 months after the second. DTaP con­
tains larger amounts of diphtheria and pertussis anti­
gens than Tdap and is not licensed for use in adults.
Inactivated adsorbed (aluminum-salt-precipitated) 
tetanus and diphtheria toxoid (Td) has been the stan­
dard booster vaccine for adults. A booster dose of Td is 
recommended every 10 years. Persons 11-64 years old 
who have completed a primary childhood series and 
have not yet received Tdap should receive a single dose 
of Tdap at the time of their next scheduled routine Td 
booster. Tdap can be given less than 10 years after the 
last Td to provide pertussis protection before travel.
TICK-BORNE ENCEPHALITIS (TBE) —  TBE 
occurs in temperate areas of Europe and Asia, from 
eastern France to northern Japan, and from northern 
Russia to Albania.28,29 The risk is greatest from April 
to November. Humans acquire the disease through the 
bite of a tick or, rarely, from eating unpasteurized dairy 
(mostly goat) products. Immunization is recommended 
only for travelers who will spend extensive time out­
doors in rural areas. The vaccine, which is not 
approved in the US but is available in Canada and 
Europe (Encepur -  Novartis; FSME-Immun -  Baxter 
AG), is usually given in 3 doses over 9-12 months, but 
can be given (Encepur) over 3 weeks (0, 7 and 21 
days). FSME-Immun can be obtained in Canada by 
contacting the Special Access Programme, Health 
Canada (613-941-2108).
The usual duration of protection after the primary 
series is 3 years; with the accelerated schedule of
Encepur, it may be only 12-18 months. Boosters give 
5 years of protection for patients <50 years old and 3 
years for those >50 years old.
TYPHOID —  Typhoid vaccine is recommended for 
travelers to South Asia and other developing countries 
in East and Southeast Asia, Central and South 
America, the Caribbean and Africa, especially if they 
will be visiting friends or relatives or traveling outside 
routine tourist destinations.30,31
A live attenuated oral vaccine (Vivotif) is available for 
adults and children >6 years old. It is taken every other 
day as a single capsule (at least 1 hour before eating) 
for a total of 4 capsules, beginning no later than 2 
weeks before departure; it protects for about 5 years. 
The capsules must be refrigerated. Antibiotics should 
be avoided for at least 72 hours before the first cap­
sule. A purified capsular polysaccharide parenteral 
vaccine (Typhim Vi) for adults and children >2 years 
old is given as a single IM dose at least 2 weeks before 
departure. Re-vaccination is recommended every 2 
years (3 years in Canada).
A combined hepatitis A/typhoid vaccine (Vivaxim -  
Sanofi Pasteur) is available in Canada.
YELLOW FEVER —  Yellow fever vaccine (YF- 
Vax), a single-dose attenuated live virus vaccine pre­
pared in eggs, should be given at least 10 days before 
travel to endemic areas, which include much of tropi­
cal South America and sub-Saharan Africa between 
15°N and 15°S.32 Some countries in Africa require an 
International Certificate of Vaccination against yellow 
fever, or a physician’s waiver letter, from all entering 
travelers; other countries in Africa, South America 
and Asia require evidence of vaccination from travel­
ers coming from or traveling through endemic or 
infected areas. The vaccine is available in the US only 
from providers certified by state health departments.33 
Boosters are given every 10 years, but immunity 
probably lasts much longer. If other injectable or 
intranasal live vaccines are not administered simulta­
neously with yellow fever vaccine, administration 
should be separated by one month to avoid a dimin­
ished immune response to the vaccines.
Yellow fever vaccine is contraindicated in travelers 
who have symptomatic HIV infection (and possibly in 
those with CD4 counts <200 cells/mm3), are immuno­
compromised or have egg allergy. Yellow fever vac­
cine-associated viscerotropic disease, a severe sys­
temic illness that can cause fatal organ failure, has 
been reported rarely. It has occurred only in first-time 
recipients, especially those with thymus disorders. 
Vaccine-associated neurologic disease (encephalitis,
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Guillain-Barre, Bell’s palsy) has also occurred. The 
vaccine should be avoided if  possible in infants <9 
months old and it is contraindicated in infants <6 
months old.34 Travelers >60 years of age also have a 
relatively high risk of systemic adverse effects.35
The most common cause of travelers’ diarrhea, usual­
ly a self-limited illness lasting several days, is infec­
tion with noninvasive enterotoxigenic (ETEC) or 
enteroaggregative (EAEC) strains of Escherichia coli. 
Infections with Campylobacter, Shigella, Salmonella, 
Aeromonas, viruses and parasites are less common. 
Children tend to have more severe illness and are par­
ticularly susceptible to dehydration. Travelers to areas 
where hygiene is poor should avoid raw vegetables, 
fruit they have not peeled themselves, unpasteurized 
dairy products, cooked food not served steaming hot, 
and tap water, including ice.
Treatm ent -  For m ild d iarrhea, loperam ide 
(Im odium , and others), an over-the-counter syn­
thetic opioid (4-mg loading dose, then 2 mg orally 
after each loose stool to a maximum of 16 mg/d for 
adults), often relieves symptoms in <24 hours. It 
should not be used if  fever or bloody diarrhea are 
present, and some patients complain o f constipa­
tion after use. Loperamide is approved for use in 
children >2 years old.
If diarrhea is moderate to severe, persists >3 days or is 
associated with high fever or bloody stools, self-treat­
ment for 1-3 days with ciprofloxacin, levofloxacin. 
norfloxacin or ofloxacin is usually recommended.36 
Azithromycin, taken as a single 1000-mg dose or 500
mg daily for 1-3 days, is an alternative37,38 and is the 
drug of choice for travelers to areas with a high preva­
lence of fluoroquinolone-resistant Campylobacter, 
such as Thailand and India.39,40 Azithromycin can be 
used in pregnant women and children (10 mg/kg/d x 
3d), and in patients who do not respond to a fluoro­
quinolone in 48 hours.
A non-absorbed oral antibiotic derived from rifampin, 
rifaximin is approved for treatment of travelers’ diar­
rhea caused by noninvasive strains of E. coli in travel­
ers >12 years of age. In clinical trials in patients with 
diarrhea mostly caused by E. coli, it has been similar in 
efficacy to ciprofloxacin, with fewer adverse effects.41 
It should not be used in infections associated with 
fever or blood in the stool or those caused by C. jeju­
ni, Salmonella, Shigella or other invasive pathogens, 
or during pregnancy.
One meta-analysis found that combinations of an anti­
bacterial plus loperamide were more effective than an 
antibacterial alone in decreasing the duration of illness.42
Packets of oral rehydration salts (Ceralyte, ORS, and 
others) mixed in potable water can prevent and treat 
dehydration, particularly in children and the elderly. 
They are available from suppliers of travel-related 
products and some pharmacies in the US, and from 
pharmacies overseas.
Prophylaxis -  Medical Letter consultants generally do 
not prescribe antibiotic prophylaxis for travelers’ diar­
rhea, but rather instruct the patient to begin self-treat­
ment when symptoms are distressing or persistent. 
Some travelers, however, such as immunocompro­
mised patients or those with time-dependent activities 
who cannot risk the temporary incapacitation associat­
ed with diarrhea, might benefit from prophylaxis.43 In 
such patients, ciprofloxacin 500 mg, levofloxacin 500 
mg, ofloxacin 300 mg or norfloxacin 400 mg can be 
given once daily during travel and for 2 days after 
return and are generally well tolerated. In one 2-week 
study among travelers to Mexico, rifaximin (200 mg 
1-3x/d) was effective in preventing travelers’ diar- 
rhea.44 Bismuth subsalicylate (Pepto-Bismol, and oth­
ers) can prevent diarrhea in travelers who take 2 tablets 
4 times a day for the duration of travel, but it is less 
effective than antibiotics. It is not recommended for 
children <3 years old.
MALARIA
No drug is 100% effective for prevention of malaria; 
travelers should be told to take protective measures 
against mosquito bites in addition to medication.45 
Countries with a risk of malaria are listed in Table 5.





Zithrom ax  (Pfizer)
1000 mg once 










500 mg bid x 1-3d 








500 mg once/d x 1-3d
44.37
Norfloxacin -  Noroxin 
(Merck)
400 mg bid x 1-3d 24.84
Ofloxacin -  generic 300 mg bid x 1-3d 32.88
Rifaximin -  Xifaxan (Salix) 200 mg tid x 3d 49.23
1. Cost of 3 days’ treatm ent based on August 2009 data from retail phar­
macies nationwide available from W olters Kluwer Health.
2. 20 500-mg tablets cost $4 at som e discount pharmacies.
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Table 5. Countries with a Risk of Malaria1
AFRICA
Angola Equatorial Guinea Niger
Benin Eritrea3 Nigeria
Botswana3 Ethiopia3 Rwanda
Burkina Faso Gabon Sao Tomé
Burundi Gambia, The and Príncipe
Cameroon Ghana Senegal
Cape Verde2 Guinea Sierra Leone
Central African Guinea-Bissau Somalia




Côte d'Ivoire Mali Togo
Democratic Mauritania Uganda







Belize34 El Salvador34 Panama36
Bolivia3 French Guiana3 Paraguay34
Brazil Guatemala3,4 Peru3
Colombia3 Guyana3 Suriname3
Costa Rica3,4 Haiti4 Venezuela3
ASIA
Afghanistan Iran3 Saudi Arabia3
Armenia34 ’4COq
J5 Sri Lanka
Azerbaijan34 Korea, North4 Tajikistan
Bangladesh3 Korea, South34 Thailand3
Bhutan3 Laos3 Timor-Leste






Papua New Solomon Islands Vanuatu
Guinea
1. O nly includes countries for which prophylaxis is recom mended. Regional 
variation in risk may exist within a country. M ore detailed information is 
available at www.cdc.gov/m alaria and by phone for medical personnel 
from the M alaria Branch of the CDC at 770-488-7788.
2. Limited to Island of Saô Tiago.
3. No m alaria in major urban areas.
4. Chloroquine is the drug of choice for prophylaxis.
5. O nly Great Exuma Island.
6. Chloroquine is recom mended in Bocas del Toro province.
7. Chloroquine is recommended except in Hainan and Yunnan provinces.
Some countries with endemic malaria transmission 
may not have malaria in the most frequently visited 
major cities and rural tourist resorts. Travelers to 
malarious areas should be reminded to seek medical 
attention if they have fever either during their trip or 
up to a year (especially during the first 2 months) after 
they return. Travelers to developing countries, where 
counterfeit and poor quality drugs are common, 
should consider buying antimalarials before travel.
CHLOROQUINE-SENSITIVE MALARIA —
Chloroquine is the drug of choice for prevention of 
malaria in the few areas that still have chloroquine- 
sensitive malaria (see Table 5, footnotes 4, 6 and 7). 
Patients who cannot tolerate chloroquine should take 
atovaquone/proguanil, doxycycline, mefloquine or, in 
some circumstances, primaquine in the same doses 
used for chloroquine-resistant malaria (see Table 6).
CHLOROQUINE-RESISTANT MALARIA —
Three drugs of choice with similar efficacy, listed with 
their dosages in Table 6, are available in the US for 
prevention of chloroquine-resistant malaria.
A fixed-dose combination of atovaquone and 
proguanil (Malarone) taken once daily is generally 
the best tolerated prophylactic,46 but it can cause 
headache, insomnia, GI disturbances and mouth ulcers. 
Single case reports of Stevens-Johnson syndrome and 
hepatitis have been published. Atovaquone/proguanil 
should not be given to patients with severe renal 
impairment (CrCl <30 mL/min). There have been iso­
lated case reports of treatment-related resistance to ato­
vaquone/proguanil in Plasmodium falciparum  in 
Africa, but Medical Letter consultants do not believe 
there is a high risk for acquisition of resistant dis- 
ease.47-50 In one study of malaria prophylaxis, ato- 
vaquone/proguanil was as effective and better tolerat­
ed than mefloquine in nonimmune travelers.51 The pro­
tective efficacy of atovaquone/proguanil against P. 
vivax is variable ranging from 84% in Indonesian New 
Guinea52 to 100% in Colombia.53 Some Medical Letter 
consultants prefer other drugs if traveling to areas 
where P. vivax predominates.
Mefloquine has the advantage of once-a-week dosing, 
but is contraindicated in patients with a history of any 
psychiatric disorder (including severe anxiety and 
depression), and also in those with a history of 
seizures or cardiac conduction abnormalities.54 
Dizziness, headache, insomnia and disturbing dreams 
are the most common CNS adverse effects. The drug’s 
adverse effects in children are similar to those in 
adults. If  a patient develops psychological or behav­
ioral abnormalities such as depression, restlessness or 
confusion while taking mefloquine, another drug 
should be substituted. Mefloquine should not be given 
together with quinine, quinidine or halofantrine due to 
potential prolongation of the QT interval; caution is 
required when using these drugs to treat patients who 
have taken mefloquine prophylaxis.
Doxycycline (Vibramycin, and others), which fre­
quently causes GI disturbances and can cause photo­
sensitivity and vaginitis, offers an inexpensive once-
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Table 6. Drugs of Choice for Prevention of Malaria1
Drug Adult dosage Pediatric dosage Duration
All Plasmodium species in chloroquine-sensitive areas2
Drug of Choice34:
Chloroquine phosphate5 500 mg (300 mg base)
(Aralen’ and others) PO once/wk
All Plasmodium species in chloroquine-resistant areas2
Drug of Choice3:





100 mg PO daily
250 mg PO once/wk9
5 mg/kg base (300 mg max) 
PO once/wk
5-8 kg: % peds tab/d 
9-10 kg: % peds tab/d 
11-20 kg: 1 peds tab/d 
21-30 kg: 2 peds tabs/d 
31-40 kg: 3 peds tabs/d 
>40 kg: 1 adult tab/d
2 mg/kg/d PO, up to 100 mg/d
5-10 kg: l/8 tab once/wk910
11-20 kg: M tabs once/wk910 
21-30 kg: % tab once/wk9 
31-45 kg: % tab once/wk9 
>45 kg: 1 tab once/wk9
Alternative:
Primaquine phosphate11’12 30 mg base PO daily 0.6 mg/kg base PO daily
Start: 1-2 wks before travel 
Stop: 4 wks after leaving 
malarious zone
Start: 1-2d before travel 
Stop: 1 wk after leaving 
malarious zone
Start: 1-2d before travel 
Stop: 4 wks after leaving 
malarious zone 
Start: 1-2 wks before travel 
Stop: 4 wks after leaving 
malarious zone
Start: 1d before travel 
Stop: 1 wk after leaving 
malarious zone
1. No drug guarantees protection against malaria. Travelers should be advised to seek medical attention if fever develops after they return. Insect repellents, insec­
ticide-impregnated bed nets and proper clothing are important adjuncts for malaria prophylaxis.
2. Chloroquine-resistant P  falciparum occurs in all malarious areas except Central Am erica (including Panama north and west of the Canal Zone), Mexico, Haiti,
the Dominican Republic, Paraguay, northern Argentina, North and South Korea, Georgia, Armenia, most of rural China and som e countries in the M iddle East
(chloroquine resistance has been reported in Yemen, Saudi Arabia and Iran). P vivax with decreased susceptib ility to chloroquine is a significant problem in 
Papua New Guinea and Indonesia.There are also a few reports of resistance from Myanmar, India, the Solomon Islands, Vanuatu, Guyana, Brazil, Colombia 
and Peru (JK Baird et al, Curr Infect Dis Rep 2007; 9:39). Ch loroquine-resistant P malariae has been reported from Sumatra (JD Maguire et al, Lancet 2002; 
360:58).
3. Prim aquine is given for prevention of relapse after infection with P vivaxor P ovale. Some experts also prescribe primaquine phosphate 30 mg base/d (0.6 mg
base/kg/d for children) for 14d after departure from areas where these species are endemic (Presum ptive Anti-Relapse Therapy [PART], “term inal prophylax­
is”). S ince this is not always effective as prophylaxis (E Schwartz et al, N Engl J Med 2003; 349:1510), others prefer to  rely on surveillance to detect cases
when they occur, particularly when exposure was limited or doubtful. See also footnote 11.
4. Alternatives for patients who are unable to take chloroquine include atovaquone/proguanil, mefloquine, doxycycline or primaquine dosed as for chloroquine-resistant areas.
5. Chloroquine should be taken with food to decrease gastrointestinal adverse effects. If chloroquine phosphate is not available, hydroxychloroquine sulfate is as 
effective; 400 mg of hydroxychloroquine sulfate is equivalent to 500 mg of chloroquine phosphate.
6. Atovaquone/proguanil is available as a fixed-dose combination tablet: adult tablets (Malarone; 250 mg atovaquone/100 mg proguanil) and pediatric tablets 
(Malarone Pediatric-; 62.5 mg atovaquone/25 mg proguanil).To enhance absorption and reduce nausea and vomiting, it should be taken with food or a milky 
d rink .T he  drug should not be given to patients with severe renal im pairm ent (creatinine clearance <30 mL/min).
7. Doxycycline should be taken with adequate water to  avoid esophageal irritation. It can be taken with food to  m inim ize gastrointestinal adverse effects. It is con­
traindicated in children <8 years old.
8. In the US, a 250-mg tablet of mefloquine contains 228 mg m efloquine base. O utside the US, each 275-mg tablet contains 250 mg base. Mefloquine can be 
given to patients taking B-blockers if they do not have an underlying arrhythmia; it should not be used in patients with conduction abnormalities. Mefloquine should 
not be taken on an em pty stomach; it should be taken with at least 8 oz. of water.
9. Most adverse events occur w ith in 3 doses. Some M edical Letter consultants favor starting mefloquine 3 weeks prior to travel and monitoring the patient for 
adverse events; th is allows tim e to change to an alternative regimen if m efloquine is not tolerated.
10. For pediatric doses < 1/2  tablet, it is advisable to have a pharmacist crush the tablet, estimate doses by weighing, and package them in gelatin capsules. The re  is 
no data  for use in children <5 kg, but based on dosages in other we ight groups, a dose of 5 m g/kg can be used.
11. Patients should be screened for G -6-PD de fic iency before trea tm ent w ith  prim aquine. It should be taken w ith  food to  m inim ize nausea and abdom inal pain.
12. Not FDA-approved for th is  indication.
daily alternative. Doxycycline should not be taken 
concurrently with antacids, oral iron or bismuth salts
A fourth drug, primaquine phosphate, can also be 
used for prophylaxis, especially in areas where P. vivax 
is the predominant species, but in other areas should be 
reserved for travelers unable to take any other drug; it 
is somewhat less effective than the alternatives against 
P  falciparum. However, several studies have shown
that daily primaquine can provide effective prophylax­
is against chloroquine-resistant P  falciparum  and P. 
vivax.55 Some experts also prescribe primaquine for 
prophylaxis after departure from areas where P. vivax 
and P. ovale are endemic (see Table 6, footnote 3).
Primaquine can cause hemolytic anemia in patients 
with glucose-6-phosphate dehydrogenase (G-6-PD) 
deficiency, which is most common in African, Asian,
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and M editerranean peoples. Travelers should be 
screened for G-6-PD deficiency before treatment with 
the drug. Primaquine should be taken with food to 
reduce GI effects.
MEFLOQUINE-RESISTANT MALARIA —  Doxy­
cycline or atovaquone/proguanil is recommended for 
prophylaxis against m efloquine-resistant malaria, 
which occurs in the malarious areas of Thailand and in 
the areas of Myanmar and Cambodia that border on 
Thailand. It has also been reported on the borders 
between Myanmar and China, and Laos and Myanmar, 
and in southern Vietnam.
PREGNANCY —  Malaria in pregnancy is particular­
ly serious for both mother and fetus; prophylaxis is 
indicated if travel cannot be avoided. Chloroquine has 
been used extensively and safely for prophylaxis of 
chloroquine-sensitive m alaria during pregnancy. 
Mefloquine is not approved for use during pregnancy. 
It has, however, been reported to be safe for prophy­
lactic use during the second or third trimester of preg­
nancy and possibly during early pregnancy as well.56,57 
The safety of atovaquone/proguanil in pregnancy has 
not been established, and its use is not recommended. 
However, outcomes were normal in 24 women treated 
with the combination in the second and third 
trimester,58 and proguanil alone has been used in preg­
nancy without evidence of toxicity. Doxycycline and 
primaquine are contraindicated in pregnancy.
PREVENTION OF INSECT BITES
To minimize insect bites, travelers should wear light- 
colored, long-sleeved shirts, pants, socks and covered 
shoes. They should sleep in air conditioned or screened 
areas and use insecticide-impregnated bed nets. 
Mosquitoes that transmit malaria are most active 
between dusk and dawn; those that transmit dengue 
fever bite during the day, particularly during early 
morning and late afternoon.59
DEET —  The most effective topical insect repellent is 
N, N-diethyl-m-toluamide (D eET).60 Applied on 
exposed skin, DEET repels mosquitoes, as well as 
ticks, chiggers, fleas, gnats and some flies. DEET is 
available in formulations of 5-100% even though 
increasing the concentration above 50% does not seem 
to improve efficacy. Medical Letter consultants prefer 
concentrations of 30-35%. A long-acting DEET for­
mulation originally developed for the US Armed 
Forces (US Army Extended Duration Topical Insect 
and Arthropod Repellent -  EDTIAR) containing 25­
33% DEET (Ultrathon) protects for 6-12 hours. A 
microencapsulated sustained-release formulation con­
taining 20% DEET (Sawyer Controlled Release) is
also available and can provide longer protection than 
similar concentrations of other DEET formulations.
According to the CDC, DEET is probably safe in chil­
dren and infants >2 months old; the American 
Academy of Pediatrics recommends use of concentra­
tions containing no more than 30%. One study found 
that applying DEET regularly during the second and 
third trimesters of pregnancy did not result in any 
adverse effects on the fetus.61 DEET has been shown 
to decrease the effectiveness of sunscreens when it is 
applied after the sunscreen; nevertheless, sunscreen 
should be applied first because it may increase the 
absorption of DEET when DEET is applied first.62
PICARIDIN —  Picaridin has been available in 
Europe and Australia for many years. Data on the 7% 
and 15% formulations (Cutter Advanced) currently 
sold in the US are limited. The 20% formulation 
(Natrapel 8 Hour; GoReady) has been shown to pro­
tect for up to 8 hours; in clinical trials it has been about 
as effective as 20% DEET.63-65
PERMETHRIN —  An insecticide available in liquid 
and spray form, permethrin (Duranon, Permanone, 
and others) can be used on clothing, mosquito nets, 
tents and sleeping bags for protection against mosqui­
toes and ticks. After application to clothing, it remains 
active for several weeks through multiple launderings. 
Using permethrin-impregnated mosquito nets while 
sleeping is helpful when rooms are not screened or air- 
conditioned. If  bednets or tents are immersed in the 
liquid, the effect can last for about 6 months. The com­
bination of DEET on exposed skin and permethrin on 
clothing provides increased protection.
SOME OTHER INFECTIONS
DENGUE —  Dengue fever is a viral disease transmit­
ted by mosquito bites that occurs worldwide in tropical 
and subtropical areas, including cities. Epidemics have 
occurred in recent years in Southeast Asia (especially 
Thailand), South Central Asia, sub-Saharan Africa, the 
South Pacific and Australia, Central and South 
America and the Caribbean. It has also been reported 
in travelers from the US vacationing at popular tourist 
destinations in Puerto Rico, the US Virgin Islands and 
Mexico.66 Prevention of mosquito bites during the day, 
particularly in early morning and late afternoon, is the 
primary way to protect against dengue fever; no vac­
cine is currently available.
LEPTOSPIROSIS —  Leptospirosis, a bacterial dis­
ease that occurs in many domestic and wild animals, is 
endemic worldwide, but the highest incidence is in 
tropical and subtropical areas. Transmission to humans
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usually occurs through contact with fresh water or 
damp soil contaminated by the urine of infected ani­
mals.67 Travelers at increased risk, such as adventure 
travelers and those who engage in recreational water 
activities, should consider prophylaxis with doxycy- 
cline 200 mg orally once a week, beginning 1-2 days 
before and continuing throughout the period of expo­
sure. No human vaccine is available in the US.
NON-INFECTIOUS RISKS OF TRAVEL
Many non-infectious risks are associated with travel. 
Injuries, particularly traffic accidents and drowning, 
which account for the majority of travel-related deaths, 
and sunburn occur in many travelers.
HIGH ALTITUDE ILLNESS —  Rapid exposure to 
altitudes >8,000 feet (2500 meters) may cause acute 
mountain sickness (headache, fatigue, nausea, anorex­
ia, insomnia, dizziness); pulmonary and cerebral 
edema can occur.68 Sleeping altitude appears to be 
especially important in determining whether symp­
toms develop. The most effective preventive measure 
is pre-acclimatization by a 2- to 4-day stay at interme­
diate altitude (6000-8000 feet) and gradual ascent to 
higher elevations.
Acetazolamide, a carbonic anhydrase inhibitor taken in 
a dosage of 125-250 mg twice daily (or 500 mg daily 
with the slow-release formulation Diamox Sequels) 
beginning 1-2 days before ascent and continuing at 
high altitude for 48 hours or longer, decreases the inci­
dence and severity of acute mountain sickness.69 The 
recommended dose for children is 5 mg/kg/d in 2 or 3 
divided doses. Although acetazolamide, a sulfone, has 
little cross-reactivity with sulfa drugs, hypersensitivity 
reactions to acetazolamide are more likely to occur in 
those who have had severe (life-threatening) allergic 
reactions to sulfa drugs.70
Symptoms can be treated after they occur by descent to 
a lower altitude or by giving supplemental oxygen, 
especially during sleep. When descent is impossible, 
dexamethasone (Decadron, and others) 4 mg q6h, 
acetazolamide 250-500 mg q12h, or the two together, 
may help. Nifedipine (Procardia, and others), 20-30 
mg twice daily may also be helpful.
VENOUS THROMBOEMBOLISM —  Prolonged 
immobilization, particularly during air travel, increas­
es the risk of lower extremity deep vein thrombosis 
(DVT). Travelers with risk factors for thrombosis (past 
history of thrombosis, obesity, malignancy, increased 
platelets) are at even higher risk. Nevertheless, flight- 
related symptomatic pulmonary embolism is rare.71
To minimize the risk, travelers should be advised to 
walk around or, if necessary, exercise while sitting by 
flexing/extending ankles and knees, to drink extra flu­
ids, and to avoid alcohol and caffeine. Compression 
stockings can decrease the risk of asymptomatic 
DVT.72 Giving a single dose of a low-molecular- 
weight heparin as prophylaxis to travelers at high risk 
reduced the incidence of DVT in a clinical trial.73
JET LAG —  Disturbance of body and environmental 
rhythms resulting from a rapid change in time zones 
gives rise to je t lag, which is characterized by insom­
nia, decreased quality of sleep, loss of concentration, 
irritability and GI disturbances. It is usually more 
severe after eastward travel.74
A variety of interventions have been tried, but none is 
proven to be effective. Shifting daily activities to cor­
respond to the time zone of the destination country 
before arrival along with taking short naps, remaining 
well hydrated, avoiding alcohol and pursuing activities 
in sunlight on arrival may help. The dietary supple­
ment melatonin (0.5-5 mg started on the first night of 
travel and continued for 1-5 days after arrival) has 
been reported to facilitate the shift of the sleep-wake 
cycle and decrease symptoms in some patients. A pro­
gram of appropriately timed light exposure and avoid­
ance in the new time zone may adjust the “body clock” 
and reduce jet lag.75 In one study, zolpidem (Ambien, 
and others) started the first night after travel and taken 
for 3 nights was helpful.76
MOTION SICKNESS —  Therapeutic options for 
motion sickness remain limited.77 A transdermal patch 
or oral formulation of the prescription cholinergic 
blocker scopolamine can decrease symptoms. 
Transderm Scop is applied to the skin behind the ear at 
least 4 hours before exposure and changed, alternating 
ears, every 3 days. The oral 8-hour tablet (Scopace) is 
taken 1 hour before exposure. Oral promethazine 
(Phenergan, and others) is a highly sedating alterna­
tive. Over-the-counter drugs such as dimenhydrinate 
(Dramamine, and others) or meclizine (Bonine, and 
others) are less effective, but may be helpful for milder 
symptoms.
1. DR Hill et al. The practice of travel medicine: guidelines by the 
Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.
2. Adult immunization. Treat Guidel Med Lett 2009; 7:27.
3. D Daniels et al. Surveillance for acute viral hepatitis-United States,
2007. MMWR Surveill Summ 2009; 58(SS03):1.
4. P Van Damme et al. Hepatitis A booster vaccination: is there a need? 
Lancet 2003; 362:1065.
5. JN Zuckerman et al. Hepatitis A and B booster recommendations: 
implications for travelers. Clin Infect Dis 2005; 41:1020.
6. S Iwarson et al. Excellent booster response 4 to 8 years after a single 
primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004; 
11:120.
92 Treatment Guidelines from The Medical Letter • Vol. 7 (Issue 87) • November 2009
Advice for Travelers
7. Advisory Committee on Immunization Practices (ACIP) Centers for 
Disease Control and Prevention (CDC). Update: prevention of hepati­
tis A after exposure to hepatitis A virus and in international travelers. 
Updated recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 
2007; 56:1080.
8. BAConnor and DJ Patron. Use of an accelerated immunization sched­
ule for combined hepatitis A and B protection in the corporate travel­
er. J Occup Environ Med 2008; 50:945 .
9. DO Freedman and K Leder. Influenza: changing approaches to pre­
vention and treatment in travelers. J Travel Med 2005; 12:36.
10. Seasonal trivalent influenza vaccine for 2009-2010. Med Lett Drugs 
Ther 2009; 51:73.
11. Centers for Disease Control and Prevention (CDC). Use of northern 
hemisphere influenza vaccines by travelers to the southern hemi­
sphere. MMWR Morb Mortal Weekly Rep 2009; 58:312.
12. H1N1 Vaccine for prevention of pandemic influenza. Med Lett Drugs 
Ther 2009; 51:77.
13. MR Buhl and L Lindquist. Japanese encephalitis in travelers: review of 
cases and seasonal risk. J Travel Med 2009; 16:217.
14. ACIP provisional recommendations for the use of Japanese encephali­
tis virus vaccines, June 24, 2009. Available at www.cdc.gov/vac- 
cines/recs/provisional/downloads/je-july2009-508.pdf. Accessed 
October 5, 2009.
15. A new Japanese encephalitis vaccine (Ixiaro). Med Lett Drugs Ther 
2009; 51:66.
16. ST Duggan and GL Plosker. Japanese enecphalitis vaccine (inactivat­
ed, adsorbed) [IXIARO]. Drugs 2009; 69:115.
17. ACIP Provisional Recommendations for measles-mumps-rubella 
(MMR) ‘evidence of immunity’ requirements for healthcare personnel. 
Available at: www.cdc.gov/vaccines/recs/provisional/default.htm. 
Accessed October 5, 2009.
18. A Wilder-Smith. Meningococcal disease: risk for international trav­
ellers and vaccine strategies. Travel Med Infect Dis 2008; 6:182.
19. OO Bilukha and N Rosenstein; National Center for Infectious 
Diseases, Centers for Disease Control and Prevention (CDC). 
Prevention and control of meningococcal disease. recommendations of 
the Advisory Committee on Immunization Practices (ACIP). MMWR 
Recomm Rep 2005; 54 (RR-7):1.
20. Committee to Advise on Tropical Medicine and Travel (CATMAT). 
Statement on meningococcal vaccination for travellers. An Advisory 
Committee Statement (ACS). Can Commun Dis Rep 2009; 35(ACS- 
4):1.
21. CDC Vaccine safety updates. GBS and Menactra meningococcal vac­
cine. Available at: www.cdc.gov/vaccinesafety/updates/gbsfact 
sheet.htm. Accessed October 5, 2009.
22. Centers for Disease Control and Prevention (CDC). Update on vac­
cine-derived polioviruses—worldwide, January 2008-June 2009. 
MMWR Morb Mortal Wkly Rep 2009; 58:1002.
23. CE Rupprecht and RV Gibbons. Clinical practice. Prophylaxis against 
rabies. N Engl J Med 2004; 351:2626.
24. FX Meslin. Rabies as a traveler’s risk, especially in high-endemicity 
areas. J Travel Med 2005; 12 Suppl 1:S30.
25. ACIP provisional recommendations for the prevention of human 
rabies. July 10, 2009. Available at www.cdc.gov/vaccines/recs/provi- 
sional/downloads/rabies-July 2009-508.pdf. Accessed October 5,
2009.
26. SE Manning et al. Human rabies prevention—United States, 2008: rec­
ommendations of the Advisory Committee on Immunization Practices 
(ACIP). MMWR Recomm Rep 2008; 57 (RR-3):1.
27. Adacel and Boostrix: Tdap vaccines for adolescents and adults. Med 
Lett Drugs Ther 2006; 48:5.
28. A Banzhoff et al. Protection against tick-borne encephalitis (TBE) for 
people living in and traveling to TBE-endemic areas. Travel Med 
Infect Dis 2008; 6:331.
29. U Kunze. Is there a need for a travel vaccination against tick-borne 
encephalitis? Travel Med Infect Dis 2008; 6:380.
30. MF Lynch et al. Typhoid fever in The United States, 1999-2006.
JAM A2009; 302:859.
31. JAWhitaker et al. Rethinking typhoid fever vaccines: implications for 
travelers and people living in highly endemic areas. J Travel Med 
2009; 16:46.
32. ED Barnett. Yellow fever: epidemiology and prevention. Clin Infect 
Dis 2007; 44:850.
33. Search for yellow fever vaccination clinics. Updated Jan 28, 2008. 
Available at: wwwn.cdc.gov/travel/yellow-fever-vaccination-clinics- 
search.aspx. Accessed Oct 5, 2009.
34. AW McMahon et al. Neurologic disease associated with 17D-204 yel­
low fever vaccination: a report of 15 cases. Vaccine 2007; 25:1727.
35. ED Barnett et al. Yellow fever vaccines and international travelers. 
Expert Rev Vaccines 2008; 7:579.
36. HL DuPont et al. Expert review of the evidence base for self-therapy 
of travelers’ diarrhea. J Travel Med 2009; 16:161.
37. JAAdachi et al. Azithromycin found to be comparable to levofloxacin 
for the treatment of US travelers with acute diarrhea acquired in 
Mexico. Clin Infect Dis 2003; 37:1165.
38. CD Ericsson et al. Loperamide plus azithromycin more effectively 
treats travelers’ diarrhea in Mexico than azithromycin alone. J Travel 
Med 2007; 14:312.
39. D Jain et al. Campylobacter species and drug resistance in a north 
Indian rural community. Trans R Soc Trop Med Hyg 2005; 99:207.
40. DR Tribble et al. Traveler’s diarrhea in Thailand: randomized, double­
blind trial comparing single-dose and 3-day azithromycin-based regi­
mens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.
41. AL Pakyz. Rifaximin: a new treatment for travelers’ diarrhea. Ann 
Pharmacother 2005; 39:284.
42. MS Riddle et al. Effect of adjunctive loperamide in combination with 
antibiotics on treatment outcomes in traveler’s diarrhea: a systematic 
review and meta-analysis. Clin Infect Dis 2008; 47:1007.
43. HL DuPont et al. Expert review of the evidence base for prevention of 
travelers’ diarrhea. J Travel Med 2009; 16:149.
44. HL DuPont et al. A randomized, double-blind, placebo-controlled trial 
of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005; 
142:805.
45. DO Freedman. Clinical practice. Malaria prevention in short-term trav­
elers. N Engl J Med 2008; 359:603.
46. PJ van Genderen et al. The safety and tolerance of 
atovaquone/proguanil for the long-term prophylaxis of plasmodium 
falciparum malaria in non-immune travelers and expatriates [correct­
ed]. J Travel Med 2007; 14:92.
47. E Schwartz et al. Genetic confirmation of atovaquone-proguanil-resist- 
ant Plasmodium falciparum malaria acquired by a nonimmune travel­
er to East Africa. Clin Infect Dis 2003; 37:450.
48. AFärnert et al. Evidence of Plasmodium falciparum  malaria resistant 
to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 
326:628.
49. S Kuhn et al. Emergence of atovaquone-proguanil resistance during 
treatment of Plasmodium falciparum  malaria acquired by a non­
immune North American traveller to west Africa. Am J Trop Med Hyg 
2005; 72:407.
50. CT Happi et al. Confirmation of emergence of mutations associated 
with atovaquone-proguanil resistance in unexposed Plasmodium falci­
parum isolates from Africa. Malaria J 2006; 5:82.
51. D Overbosch et al. Atovaquone-proguanil versus mefloquine for 
malaria prophylaxis in nonimmune travelers: results from a random­
ized, double-blind study. Clin Infect Dis 2001; 33:1015.
52. J Ling et al. Randomized, placebo-controlled trial of 
atovaquone/proguanil for the prevention of Plasmodium falciparum or 
Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin 
Infect Dis 2002; 35:825.
53. J Soto et al. Randomized, double-blind, placebo-controlled study of 
Malarone for malaria prophylaxis in non-immune Colombian soldiers. 
Am J Trop Med Hyg 2006; 75:430.
54. LH Chen et al. Controversies and misconceptions in malaria chemo­
prophylaxis for travelers. JAMA2007; 297:2251.
55. DR Hill et al. Primaquine: report from CDC expert meeting on malar­
Treatment Guidelines from The Medical Letter • Vol. 7 (Issue 87) • November 2009 93
Advice for Travelers
ia chemoprophylaxis I. Am J Trop Med Hyg 2006; 75:402.
56. Centers for Disease Control and Prevention. CDC Health Information 
for International Travel 2010. Atlanta: U.S. Department of Health and 
Human Services, Public Health Service, 2009, p 469.
57. BL Smoak et al. The effects of inadvertent exposure of mefloquine 
chemoprophylaxis on pregnancy outcomes and infants of US Army 
servicewomen. J Infect Dis 1997; 176:831.
58. R McGready et al. The pharmacokinetics of atovaquone and proguanil 
in pregnant women with acute falciparum malaria. Eur J Clin 
Pharmacol 2003; 59:545.
59. Committee to Advise on Tropical Medicine and Travel (CATMAT). 
Statement on personal protective measures to prevent arthropod bites. 
Can Commun Dis Rep 2005; 31 (ACS-4):1.
60. TM Katz et al. Insect repellents: historical perspectives and new 
developments. J Am Acad Dermatol 2008; 58:865.
61. R McGready et al. Safety of the insect repellent N,N-diethyl-M-tolu- 
amide (DEET) in pregnancy. Am J Trop Med Hyg 2001; 65:285.
62. Sunscreens: an update. Med Lett Drugs Ther 2008; 50:70.
63. A Badolo et al. Evaluation of the sensitivity of Aedes aegypti and 
Anopheles gambiae complex mosquitoes to two insect repellents: 
DEET and KBR 3023. Trop Med Int Health 2004; 9:330.
64. SP Frances et al. Laboratory and field evaluation of commercial repel­
lent formulations against mosquitoes (diptera: culcidae) in 
Queensland, Australia. Aust J Entomol 2005; 44:431.
65. C Constantini et al. Field evaluation of the efficacy and persistence of 
insect repellents DEET, IR3535, and KBR 3023 against Anopheles 
gambiae complex and other Afrotropical vector mosquitoes. Trans R 
Soc Trop Med Hyg 2004; 98:644.
66. AWilder-Smith and DJ Gubler. Geographic expansion of dengue: the 
impact of international travel. Med Clin North Am 2008; 92:1377.
67. A Pavli and HC Maltezou. Travel-acquired leptospirosis. J Travel Med 
2008; 15:447.
68. SA Gallagher and PH Hackett. High-altitude illness. Emerg Med Clin 
North Am 2004; 22:329.
69. B Basnyat et al. Acetazolamide 125 mg BD is not significantly differ­
ent from 375 mg BD in the prevention of acute mountain sickness: 
the prophylactic acetazolamide dosage comparison for efficacy 
(PACE) trial. High Alt Med Biol 2006; 7:17.
70. BL Strom et al. Absence of cross-reactivity between sulfonamide 
antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003; 
349:1628.
71. D Chandra et al. Meta-analysis: travel and risk for venous throm­
boembolism. Ann Intern Med 2009; 151:180.
72. M Clarke et al. Compression stockings for preventing deep vein 
thrombosis in airline passengers. Cochrane Database Syst Rev 2006; 
(2):CD004002.
73. MR Cesarone et al. Venous thrombosis from air travel: the LON- 
FLIT3 study-prevention with aspirin vs low-molecular-weight 
heparin (LMWH) in high-risk subjects: a randomized trial. Angiology 
2002; 53:1.
74. RL Sack. The pathophysiology ofjet lag. Travel Med Infect Dis 2009; 
7:102.
75. J Waterhouse et al. Jet lag: trends and coping strategies. Lancet 2007; 
369:1117.
76. AO Jamieson et al. Zolpidem reduces the sleep disturbance of jet lag. 
Sleep Med 2001; 2:423.
77. JF Golding and MA Gresty. Motion sickness. Curr Opin Neurol 2005; 
18:29.
Coming Soon in Treatment Guidelines:
Antifungal Drugs -  December 2009 
Drugs for Eye Disorders -  January 2010
Treatment Guidelines
fro m  T h e  M e d ic a l L e tte r
EDITOR IN CHIEF: Mark Abramowicz, M.D.
EXECUTIVE EDITOM: Gianna Zuccotti , M.D., M.P.H., F.A.C.P., Harvard Medical 
School
EDITOR: Jean-Marie Pflomm, Pharm.D.
ASSISRANT EDITORS, DRUG INFORMATION: Susan M. Daron, Pharm.D., 
Blaine IA. Houst, Pharm.D., Corinne E. Zanone, Pharm.D.
CONTRIBUTING EDITORS:
COrlW. Bazil, M.D., Ph.Q,Columbia University College of Physicians and Surgeons
Vunessa K. Dalton, M.D., M.PH., University of Michigan Medical School
Aric J. Epstein, M.D., Albert Einstein College of Medicine
David N. Juurlink, BRhm, M.D., PhD, Ssnnybrook Health Sciences Centre
Wchard B. Kim, M.D., University of \A/este rn Ontario
Rans MeinKrtz, M.D., University Hospital, Copenhagen
Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine
F. Estelle R. Simons, M.D., University of Manitoba
Dordan W. Smoller, M.D., Sc.D., Harvard Medical School
Neal H. Steigbigel, M.D., NewYork University/ Schoo l of Medicine
ADVISORY SOARD:
Aules CIrsch , M.D., RoCkefeller Mniversity
Gerald L. Mandell, M.D., University of Virginia School of Medicine
Dan M. Roden, M.D., VandMrbilt UniverSity Schoolef Mndicine
^IMIOR ASSOCIATEE EDITORS: Donna Goodstein, Amy Faucard 
ASSOCIATE EDITOR: Cynthia Maca|tagal Covey
^ITORIAL. FELLOW: Vince Teo B.Sc. Phm, Sunnybrook Health Sciences Centre
MANAGING EDITORo SuOie WonE 
ASSISTANE mANAGING EnTOR: Liz DEnohue 
DRODUCTION COORDINATOR: Cheryl frow n
EXECUTIVE DINTCTOR OF SALES: Gene Carbona 
FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski 
DIRECTOR OF MARKETING COMMUNICATIONS: Joanne F.Valentino 
VICE PRESIDENT AND PUBKISHER: Yosef Wissner- Levy
Founded in 1959 by 
Arthur Kallet and Harold Aaron, M.D.
Copyright and Disclaimer: The Medical Letter is an independent nonprofit organ­
ization that provides healthcare professionals with unbiased drug prescribing rec- 
ommendations.The editorial process used for its publications relies on a review of 
published and unpublished literature, with an emphasis on controlled clinical trials, 
and on the opinions of its consultants.The Medical Letter is supported solely by sub­
scription fees and accepts no advertising, grants or donations.
No part of the material may be reproduced or transmitted by any process in whole or 
in part without prior permission in writing.The editors do not warrant that all the mate­
rial in this publication is accurate and complete in every respect.The editors shall not 
be held responsible for any damage resulting from any error, inaccuracy or omission.
Subscription Services 
M a il in g  A d d re s s :  S u b s c r ip t io n s  (U S ):
T h e  M e d ic a l L e tte r  In c . 1 y e a r  - $ 9 8 ; 2  y e a rs  - $ 1 6 7 ;
1 0 0 0  M a in  S tre e t 3  y e a rs  - $ 2 3 5 . $ 4 9 /y r. fo r  s tu d e n ts ,
N e w  R o c h e lle , N Y  1 0 8 0 1 -7 5 3 7  in te rn s , re s id e n ts  a n d  fe llo w s  in th e
U S a n d  C a n a d a .
C M E : $ 4 4  fo r  2 e  c re d its .
C u s to m e r  S e rv ic e :
C a ll: 8 G G -2 1 1 -2 7 6 9  o r  91 4-235-G 5G G  
F ax : 9 1 4 -6 3 2 -1 7 3 3  E -m a il s i te  lic e n s e  in q u ir ie s  to :
W e b  S ite : w w w .m e d ic a l le t te r .o rg  in fo @ m e d ic a lle tte r .o rg  o r  c a ll
E -m a il: c u s ts e rv @ m e d ic a lle t te r .o rg  8 G G -2 1 1 -2 7 6 9  x 3 1 5 .
P e rm is s io n s :
To re p ro d u c e  a n y  p o r t io n  o f th is  is su e , 
p le a s e  e -m a il y o u r  re q u e s t to : 
p e rm is s io n s @ m e d ic a lle tte r .o rg
S p e c ia l fe e s  fo r  b u lk  s u b s c r ip t io n s . 
S p e c ia l c la s s ro o m  ra te s  a re  a v a i l­
a b le . B a c k  is s u e s  a re  $ 1 2  e a ch . 
M a jo r  c re d it c a rd s  a c c e p te d .
Copyright 2009. ISSN 1541-2782
94 Treatment Guidelines from The Medical Letter • Vol. 7 (Issue 87) • November 2009
Introducing
Treatment Guidelines'.Online Continuing Medical Education
Up to 24 credits included with your subscription
www.medicalletter.org/tgcme
For over 25 years, The Medical Letter has offered health care professionals continuing medical education (CME) with The Medical Letter on Drugs and 
Therapeutics. We are now offering CME for Treatment Guidelines from The Medical Letter in an online format only, called the Online Series. Each Online 
Series is comprised of 6 monthly exams and eligible for up to 12 credits. For those who just need a few credits, we also offer the Quick Online Credit Exam 
(earn up to 2 credits/12 questions). For more information, please visit us at www.medicalletter.org/tgcme.
Choose CME from Treatment Guidelines from The Medical Letter and earn up to 
24 Category 1 Credits per year in the format that’s right for you:
Online Series - Answer 12 questions per issue online. Earn up to 2 credits/exam. Take up to 6 short exams per six-month series and earn up to a total of 
12 credits. The Online Series is included with a paid subscription to Treatment Guidelines.
Quick Online Credit Exam - Access content for any available issue, answer 12 questions online, and earn up to 2 credits for $12.00 (available to both sub­
scribers and non-subscribers).
ACCREDITATION INFORMATION:
ACCME: The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 
The Medical Letter designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit com­
mensurate with the extent of their participation in this activity. This CME activity was planned and produced in accordance with the ACCME Essentials.
AAFP: Treatment Guidelines from The Medical Letter has been reviewed and is acceptable for up to 15 Prescribed credits by the American Academy of 
Family Physicians. AAFP accreditation begins 01/01/09. Term of approval is for one year from this date. This exam is approved for 1.25 Prescribed cred­
its. Credits may be claimed for one year from the date of this exam.
ACPE: The Medical Letter Is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This Issue 
is acceptable for 2.0 hours of Continuing Education Credit (0.2 CEU).
AANP and AAPA: The American Academy of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA) accept AMA 
Category 1 Credit for the Physician’s Recognition Award from organizations accredited by the ACCME.
AOA: This activity, being ACCME (AMA) approved, is acceptable for Category 2-B credit by the American Osteopathic Association .
MISSION:
The mission of The Medical Letter's Continuing Medical Education Program is to support the professional development of health care professionals includ­
ing physicians, nurse practitioners, pharmacists and physician assistants by providing independent, unbiased drug information and prescribing recom­
mendations that are free of industry influence. The program content includes current information and unbiased reviews of FDA-approved and off-label uses 
of drugs, their mechanisms of action, clinical trials, dosage and administration, adverse effects and drug interactions. The Medical Letter delivers educa­
tional content in the form of self-study material.
The expected outcome of the CME Program is that knowledge and consideration of the information contained in The Medical Letter and Treatment 
Guidelines can affect health care practice and ultimately result in improved patient care and outcomes.
The Medical Letter will strive to continually improve the CME program through periodic assessment of the program and activities. The Medical Letter aims 
to be a leader in supporting the professional development of health care professionals by providing continuing medical education that is unbiased and free 
of industry influence.
LEARNING OBJECTIVES:
The objective is to meet the need of health care professionals for unbiased, reliable and timely information on treatment of major diseases.
Activity participants will read and assimilate unbiased reviews of FDA-approved and off-label uses of drugs and drug classes. Participants will be able to 
select and prescribe, or confirm the appropriateness of the prescribed usage of the drugs and other therapeutic modalities discussed in Treatment 
Guidelines with specific attention to clinical evidence of effectiveness, adverse effects and patient management. Through this program, The Medical 
Letter expects to provide the prescribing health care community with educational content that they will use to make independent and informed therapeu­
tic choices in their practice.
Questions start on next page
Treatment Guidelines from The Medical Letter • Vol. 7 (Issue 87) • November 2009
DO NOT FAX OR MAIL THIS EXAM 
To take this exam, go to: 
www.medicalletter.org/tgcme
Issue 87 Questions
1. Hepatitis A vaccine is recommended for travelers going to: 7. A vaccine for tick-borne encephalitis is:
a. Russia a. not available in the US
b. Italy b. available in Canada
c. Spain c. available in Europe
d.Japan d. all of the above
Pg 83 Pg 87
2. For hepatitis B vaccination, an accelerated schedule of 0, 7 and 14 8. Travelers’ diarrhea can be treated with:
days can be used with: a. loperamide
a. Engerix-B b. azithromycin
b. Recombivax-HB c. oral rehydration salts in water




3. Off-season use of seasonal influenza vaccine should be consi- 9. Among the most effective drugs used for prevention of chloroquine-
dered for: resistant malaria, the one generally best tolerated is:
a. travelers to the tropics a. atovaquone/proguanil
b. travelers to the Southern Hemisphere b. mefloquine
c. traveling in a group with persons from the Southern c. doxycycline
Hemisphere d. primaquine phosphate
d. all of the above
Pg 85
Pg 88
10. Mosquitoes that transmit malaria are most active:
4. The preferred vaccine for adults against Japanese encephalitis is: a. in the morning
a. JE-Vax b. a t midday
b. Ixiaro c. in the late afternoon
c. JE immune globulin d. between dusk and dawn
d. None of the above
Pg 85
Pg 90
11. Which of the following is true?
5. The “meningitis belt” where meningococcal meningitis is endemic a. DEET applied after sunscreen can decrease the effective-
is in: ness of sunscreen.
a. the Balkans b. Sunscreen applied after DEET can increase absorption of
b. the M iddle East DEET.
c. Southeast Asia c. Sunscreen should be applied before DEET.
d. sub-Saharan Africa d. All o f the above
Pg 85 Pg 91
6. Unimmunized travelers bitten by a potentially rabid animal should 12. The most effective measure to prevent high-altitude illness is:
receive: a. acetazolamide 500 mg q12h
a. rabies vaccine b. dexamethasone 4 mg q6h
b. rabies immune globulin c. nifedipine 30 mg q12h
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